CVKD Stock Overview
Operates as a clinical development biopharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cadrenal Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.71 |
| 52 Week High | US$32.55 |
| 52 Week Low | US$5.40 |
| Beta | 0 |
| 11 Month Change | -13.17% |
| 3 Month Change | 87.55% |
| 1 Year Change | 75.57% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.82% |
Recent News & Updates
Shareholder Returns
| CVKD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.4% | 2.8% | 2.2% |
| 1Y | 75.6% | 11.8% | 32.6% |
Return vs Industry: CVKD exceeded the US Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: CVKD exceeded the US Market which returned 32.6% over the past year.
Price Volatility
| CVKD volatility | |
|---|---|
| CVKD Average Weekly Movement | 18.5% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CVKD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CVKD's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 4 | Quang Pham | www.cadrenal.com |
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc. Fundamentals Summary
| CVKD fundamental statistics | |
|---|---|
| Market cap | US$24.17m |
| Earnings (TTM) | -US$7.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs CVKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVKD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.61m |
| Earnings | -US$7.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CVKD perform over the long term?
See historical performance and comparison